Kintara Therapeutics (Kintara Therapeutics) 3-Year FCF Growth Rate : 41.80% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Kintara Therapeutics 3-Year FCF Growth Rate?

Kintara Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 41.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 47.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Kintara Therapeutics was 51.60% per year. The lowest was -565.20% per year. And the median was 11.10% per year.

Competitive Comparison of Kintara Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Kintara Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's 3-Year FCF Growth Rate falls into.

Kintara Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Kintara Therapeutics (OTCPK:DMPWW) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Kintara Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (Kintara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (OTCPK:DMPWW) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

KTRA:USA 3DMA:Germany

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.